DAHLIAS study - Nipocalimab in Sjögren's Disease Nipocalimab, a neonatal Fc receptor blocker that reduces circulating IgG and autoantibodies, was shown to be effective in a phase 2 trial in patients with severe Sjögren's disease. https://t.co/tpoh8YF0F1 https://t.co/jFB1RKOqDV